

PATENT ASSIGNMENT


Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHARMEXA A/S	02/18/2009
RECEIVING PARTY DATA	
Name:	BN IMMUNOTHERAPEUTICS, INC.
Street Address:	2425 Garcia Avenue
City:	Mountain View
State/Country:	CALIFORNIA
Postal Code:	94043
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7005498
CORRESPONDENCE DATA	
Fax Number:	(858)792-3785
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	858-792-8855
Email:	gormanw@bskb.com
Correspondent Name:	Birch, Stewart, Kolasch & Birch, LLP
Address Line 1:	P.O. Box 747
Address Line 4:	Falls Church, VIRGINIA 22040-0747
ATTORNEY DOCKET NUMBER:	4614-0107P
NAME OF SUBMITTER:	Leonard R. Svensson
Total Attachments: 4 source=20090226Assignment#page1.tif source=20090226Assignment#page2.tif source=20090226Assignment#page3.tif source=20090226Assignment#page4.tif	

CH \$40.00 7005498

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies): Pharmexa A/S Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies) Name: <u>BN ImmunoTherapeutics, Inc.</u> Internal Address: _____ Street Address: _____ 2425 Garcia Avenue City: <u>Mountain View</u> State: <u>California</u> Country: <u>United States of America</u> Zip: <u>94043</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of conveyance/Execution Date(s): Execution Date(s): <u>February 18, 2009</u> <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Change of Name <input type="checkbox"/> Security Agreement <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other _____			
4. Application or patent number(s): A. Patent Application No.(s) Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		<input type="checkbox"/> This document is being filed together with a new application. B. Patent No.(s) <u>7,005,498</u> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name and address to whom correspondence concerning document should be mailed: Name: <u>Leonard R. Svensson</u> <u>BIRCH, STEWART, KOLASCH & BIRCH,</u> <u>LLP</u> Internal Address: <u>Atty. Dkt.: 4614-0107P</u> Street Address: <u>12770 High Bluff Drive</u> <u>Suite 260</u> City: <u>San Diego</u> State: <u>CA</u> Zip: <u>92130</u> Phone Number: <u>(858) 792-8855</u> Fax Number: <u>(858) 792-3785</u> Email Address: <u>mailroom@bskb.com</u>		6. Total number of applications and patents involved: <input type="text" value="1"/> 7. Total fee (37 CFR 1.21(h) & 3.41) \$ <u>40.00</u> <input type="checkbox"/> Authorized to be charged by credit card <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title)	
9. Signature:  Signature <u>Leonard R. Svensson - 30,330</u> Name of Person Signing		8. Payment Information a. Credit Card Last 4 Numbers _____ Expiration Date _____ b. Deposit Account Number <u>02-2448</u> Authorized User Name <u>Leonard R. Svensson</u>	
		Total number of pages including cover sheet, attachments, and documents: <input type="text" value="4"/>	

ASSIGNMENT

WHEREAS, Pharmexa A/S, a corporation having an office at Ager Allé 1; DK-2970 Hørsholm; DENMARK, is the owner of the entire right, title and interest in and to U.S. Letters Patent No. 7,005,498, issued February 28, 2006, by previous assignment recorded in the United States Patent and Trademark Office at Reel 014301, Frame 0197;

WHEREAS, BN ImmunoTherapeutics, Inc., a corporation having an office at 2425 Garcia Avenue, Mountain View, CA 94043, USA, is desirous of acquiring the entire right, title and interest in and to the invention(s) described and claimed in said Letters Patent;

NOW, THEREFORE, for and in consideration of the sum of Ten Dollars (\$10.00) lawful money of the United States and other valuable considerations, to me in hand paid, the receipt of and sufficiency whereof are hereby acknowledged, and said Pharmexa A/S has sold, assigned and transferred and does hereby sell, assign and transfer unto the said BN ImmunoTherapeutics, Inc., its successors and assigns, its entire undivided right, title and interest in and to the said Letters Patent and the invention(s) therein contained, including the right to sue for past infringement, to be held and enjoyed by the said BN ImmunoTherapeutics, Inc., its successors and assigns the same as it would have been held and enjoyed by Pharmexa A/S, if this assignment and sale had not been made.

Pharmexa A/S, hereby represents and warrants that there are no rights or interests outstanding inconsistent with the rights and interest granted herein and that Pharmexa A/S will not execute any instrument or grant or transfer any rights or interests inconsistent therewith, and Pharmexa A/S binds itself and its heirs, executors, administrators, employees and legal representatives, as the case may be, to execute and deliver to the said BN ImmunoTherapeutics,

Inc., its successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by the said BN ImmunoTherapeutics, Inc., its successors and assigns to file applications for improvements and inventions in any country where it may elect to file such applications, and that may be necessary to vest in the said BN ImmunoTherapeutics, Inc., its successors and assigns, the title herein conveyed, or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.


AND, Pharmexa A/S further covenants and agrees, that it, its executors and administrators will, at any time upon request, communicate to the said BN ImmunoTherapeutics, Inc., its successors and assigns, any facts relating to the said invention and improvements and the history thereof, known to it or its successors and assigns, and that it will testify as to the same in any interference or other proceeding when requested to do so by the said BN ImmunoTherapeutics, Inc., its successors and assigns.

The undersigned hereby grants the law firm of Birch, Stewart, Kolasch & Birch, LLP the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, Pharmexa A/S, has hereunto set its seal this 18th day
of February 2009.

Pharmexa A/S,

By:




Achim Kaufhold

Title:

Chief Executive Officer

By:



Ole Steen Andersen

Title:

Chairman of the Board